CN101812072B - Method for preparing anti-platelet aggregation compounds - Google Patents
Method for preparing anti-platelet aggregation compounds Download PDFInfo
- Publication number
- CN101812072B CN101812072B CN2010101823741A CN201010182374A CN101812072B CN 101812072 B CN101812072 B CN 101812072B CN 2010101823741 A CN2010101823741 A CN 2010101823741A CN 201010182374 A CN201010182374 A CN 201010182374A CN 101812072 B CN101812072 B CN 101812072B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- preparation
- reaction
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HAYJPJQZXCCFFH-UHFFFAOYSA-N CC(C(C(NN)=O)N(C)CC(C=C)=C)=C Chemical compound CC(C(C(NN)=O)N(C)CC(C=C)=C)=C HAYJPJQZXCCFFH-UHFFFAOYSA-N 0.000 description 1
- PRJWHQZLCQXWCK-UHFFFAOYSA-N CC(C)=NNC(C(c(cccc1)c1Cl)N(CC1)Cc2c1[s]cc2)=O Chemical compound CC(C)=NNC(C(c(cccc1)c1Cl)N(CC1)Cc2c1[s]cc2)=O PRJWHQZLCQXWCK-UHFFFAOYSA-N 0.000 description 1
- VNWCSVDIHKOORL-UHFFFAOYSA-N CC(C)=NNC(C(c(cccc1)c1Cl)NCCc1ccc[s]1)=O Chemical compound CC(C)=NNC(C(c(cccc1)c1Cl)NCCc1ccc[s]1)=O VNWCSVDIHKOORL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical chemistry, in particular to a new method for preparing anti-platelet aggregation compounds with a structure shown in a general formula I. In the preparation route, cheap and readily available initiative materials, namely methyl alpha-bromo-2-chlorophenylacetate and thiophene-2-ethylamine, replace clopidogrel in the conventional document. Concretely, the methyl alpha-bromo-2-chlorophenylacetate is reacted with the thiophene-2-ethylamine, replace clopidogrel under the catalysis of an acid-catcher to generate an intermediate II; the intermediate II is reacted with hydrazine hydrate, acetone or 3-pentanone to generate an intermediate III; and the intermediate III undergoes cyclization to generate the compounds in the formula I. The method has the advantages of mild reaction conditions, simple and safe operating process, and easy industrial production; and the product has stable quality, high purity and high yield; compared with that of the synthetic process provided by the conventional document, the production cost is greatly reduced; and in the formula I, R refers to methyl or ethyl.
Description
Technical field
The invention belongs to technical field of pharmaceutical chemistry, be specifically related to the compound method of one type of anti-platelet aggregation compounds, relate in particular to the industrial process of this type anti-platelet aggregation compounds.
Background technology
Thrombosis can cause the heart, brain, pulmonary circulation illness such as Acute Myocardial Infarction, apoplexy, pulmonary infarction, is threatening human beings'health and life, also is common complication and the inaccessible again factor of intervention property postangioplasty in the surgical operation.Though the thromboembolism treatment of carrying out in recent years, PCI even operative treatment make acute myocardial infarction and treatment of cerebral obtain the progress that attracts people's attention; Patient's salvage success rate improves greatly; Quality of life has also had tangible improvement, but the cardiovascular and cerebrovascular disease disability rate is after all up to 30%.Therefore the drug development of prevention and treatment cardiovascular and cerebrovascular disease becomes the focus of paying close attention in recent years and studying.Cause thrombotic factor a lot, as thrombocyte stagnate in the lip-deep adhesion of vessel wall and gathering, the blood flow stasis of blood of damage, the activation of thrombin impels the formation of zymoplasm, antiplasmin activity is low inferior, can both impel thrombosis.Thrombocyte is thrombotic essential material in these factors, thus suppress hematoblastic accumulate in the prevention of thrombus disease and treat in play an important role.ADP (ADP) is the important agonist that platelet activation, buildup effect amplify, and suppressing the thrombocyte effect through the blocking-up adp receptor has become the important means that stops pathologic thrombosis (coronary heart disease, cerebro-vascular diseases, pulmonary infarction, thrombophlebitis etc.) and myocardial infarction, unstable angina pectoris, peripheral vascular disease, congestive heart failure etc.
Clopidogrel is the adp receptor suppressor factor class antiplatelet drug of a present clinical line, because it is the extremely weak oily matter of alkalescence, needs and strong acid ability salify.It is unstable that its salt is met moisture, and free alkali is separated out, and purifying has certain difficulty.And because the strongly-acid of its salt also can receive certain restriction aspect preparation.Patent ZL200510016205.X provides a kind of new A DP receptor-blocking agent class antiplatelet formula I compound, when having excellent activity, has more superior physico-chemical property compared to clopidogrel.Because its free alkali itself is solid, the stability of its salt is also better, is easy to purifying and preparation.
Chemical name:
(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-THTP is [3,2-c] pyridine-5-yl also)]-N '-[(dimethyl-) methene base] acethydrazide (when R is a methyl);
(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-THTP is [3,2-c] pyridine-5-yl also)]-N '-[(diethylammonium) methene base] acethydrazide (when R is an ethyl).
Chemical structure:
Wherein R is methyl or ethyl.
The compound method of this compound of putting down in writing among the patent ZL200510016205.X is following:
In the reaction flask that stirring, condensing surface, TM are housed, add clopidogrel 38g, absolute ethyl alcohol 30mL, stir down slowly heating; Make the reaction raw materials dissolving, add 45.6g Hydrazine Hydrate 80 (80%), continue to be heated to backflow; Insulation reaction 4 hours, (the flaggy demonstration reacts completely).Solvent is to the greatest extent steamed in decompression then, steams and finishes, and in resistates, adds 50mL zero(ppm) water and 30mL methylene dichloride, fully stirs, and tells organic layer, and water layer merges organic layer with 3 * 30mL dichloromethane extraction, uses the SODIUM SULPHATE ANHYDROUS 99PCT thorough drying.Methylene dichloride is to the greatest extent steamed in decompression, white solid 23.4g (HPLC:97.16), m.p.139.0～139.3 ℃.
In the reaction flask that stirring, condensing surface, TM are housed, add hydrazides thing 4g, anhydrous methanol 40mL, start stirring, heating makes its dissolving.Continue to be heated to 40 ℃, drip 0.79g acetone, finish, insulation reaction 3 hours (the flaggy demonstration reacts completely).Stopped reaction, cooling has solid to generate.Filter, anhydrous methanol 3 * 2mL washing, drying gets solid product (HPLC:99.8%).M.p.169.1～170.8 ℃, Rf=0.3 [single-point, developping agent: sherwood oil (60-90 ℃): ETHYLE ACETATE=1: 1].
There is following shortcoming in the present technique scheme:
1. need to buy clopidogrel be raw material to this compound method, and cost is higher, is not suitable for industrialized production.
2. operation steps is comparatively loaded down with trivial details, repeatedly reaction solution is carried out aftertreatment, if be used for industrialized production, not only wasting a large amount of reagent increases cost, does not also meet environmental requirement.
3. use a large amount of Hydrazine Hydrate 80s, be unfavorable for labour protection.
Summary of the invention
The present invention is directed to the deficiency of prior art; A kind of method of preparation I compound of suitable industrialized production is provided; Its purpose is to overcome the existing high shortcoming of compound method cost of material, when guaranteeing quality product, selects the cheap raw material that is easy to get for use; Thereby reduce production costs, be fit to large-scale industrialization production.
Technical scheme provided by the invention is following:
2-(2-chloro-phenyl-)-2-bromo-methyl acetate and 2-(thiophene-2-yl) ethamine reacts under the catalysis of acid binding agent, generates intermediate II.Intermediate II and Hydrazine Hydrate 80, acetone or propione reaction generate intermediate III.Intermediate III cyclization reaction production I compound.
Wherein R is methyl or ethyl.
With 2-(2-chloro-phenyl-)-2-bromo-methyl acetate with dissolvings such as methylene dichloride, trichloromethane, toluene, dioxane.Add acid binding agents such as triethylamine, pyridine, salt of wormwood, yellow soda ash, sodium hydrogencarbonate, saleratus, sodium hydroxide or Pottasium Hydroxide.Add 2-(thiophene-2-yl) ethamine stirring reaction again, generate intermediate II.With the solution of intermediate II, be warming up to 50～60 ℃ of mixed solutions that add Hydrazine Hydrate 80 and acetone or propione, reaction makes intermediate III; Intermediate III is dissolved in organic acid or mineral acid, with formaldehyde the Pictet-Spengler reaction takes place, and makes formula I compound.
Wherein the concentration of Hydrazine Hydrate 80 is 60-90%; The mol ratio of intermediate II, Hydrazine Hydrate 80 and acetone or propione is 1: (1-1.2): (1-1.2).Organic acid that Pictet-Spengler reaction is used or mineral acid are wherein a kind of of formic acid, acetate, hydrochloric acid, sulfuric acid; Temperature of reaction is 30～100 ℃; The mol ratio of compound III, acid and formaldehyde is 1: (1-4): (1-2).
The present invention compared with prior art, its remarkable advantage is:
1. replace clopidogrel with starting raw material 2-cheap and easy to get (2-chloro-phenyl-)-2-bromo-methyl acetate and 2-(thiophene-2-yl) ethamine, greatly reduce production cost.
2. reaction conditions is gentle, and simple and safe operation process is easy to realize suitability for industrialized production.Reaction times is short, need not heat, less demanding to equipment, and it is low to consume energy.Practiced thrift the energy, facility investment and running cost, effects of energy saving and emission reduction is obvious, meets the requirement of low-carbon economy.
3. significantly reduce the Hydrazine Hydrate 80 usage quantity, be beneficial to labour protection.
4. constant product quality, purity is high, and productive rate is high, can reach the requirement of industrial amplification production.
Embodiment
The present invention can realize through following concrete technology:
Reference implementation example: the synthesizing of 2-(2-chloro-phenyl-)-2-[2-(thiophene-2-yl) ethamine] methyl acetate (II)
In the 250mL reaction flask, add 2-(2-chloro-phenyl-)-2-bromo-methyl acetate 26.4g (0.1mol) and 100mL methylene dichloride, start stirring, dissolve clear back and add 27.6g (0.2mol) Anhydrous potassium carbonate, add 2-(thiophene-2-yl) ethamine 12.7g (0.1mol) in batches.After finishing, be warming up to back flow reaction 3 hours (the flaggy demonstration reacts completely).Stopped reaction filters.With the small portion evaporate to dryness of filtrating, white solid product (HPLC:98.4%).
1H?NMR(DMSO-d
6，400MHz)δ：2.997～3.068(m，1H)，3.107～3.177(m，1H)，3.253～3.339(m，2H)，3.725(s，3H)，5.588(s，1H)，6.903～6.909(d，1H)，6.941～6.962(m，1H)，7.364～7.379(q，1H)，7.463～7.532(m，2H)，7.599～7.622(q，1H)，7.756～7.779(m，1H)，10.456(bro，1H)。
Embodiment 1: intermediate III-1 synthetic
With the solution of gained intermediate II of last step, be warming up to 50 ℃, stir the mixed solution that adds 60% Hydrazine Hydrate 80 8.34g (0.1mol) and acetone 5.81g (0.1mol) down, in 50 ℃ of reaction 1h (the flaggy demonstration reacts completely).Stopped reaction, cooling has solid to generate.Filter, drying gets solid product 30.3g (HPLC:99.8%), yield 86.7%.Rf=0.41 [single-point, developping agent: ETHYLE ACETATE: sherwood oil (60-90 ℃)=1: 1].
Embodiment 2:Synthesizing of intermediate III-2
With the solution of gained intermediate II of last step, be warming up to 60 ℃, stir the mixed solution that adds 90% Hydrazine Hydrate 80 6.67g (0.12mol) and propione 10.3g (0.12mol) down, in 60 ℃ of reaction 0.5h (the flaggy demonstration reacts completely).Stopped reaction, cooling has solid to generate.Filter, drying gets solid product 33.4g (HPLC:99.0%), yield 87.4%.Rf=0.45 [single-point, developping agent: ETHYLE ACETATE: sherwood oil (60-90 ℃)=1: 1].
Embodiment 3:(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-THTP is [3,2-c] pyridine-5-yl also)]-N '-[(dimethyl-) methene base] acethydrazide
In the 250mL reaction flask that stirring, condensing surface, TM are housed, add 3.5g (0.01mol) intermediate III-1, add 15% formic acid solution 10mL (0.04mol), stir adding 0.6g (0.02mol) formaldehyde down.Be warming up to 50 ℃ and continue reaction 0.5h (the flaggy demonstration reacts completely).Stopped reaction, with 3 * 10mL dichloromethane extraction, anhydrous sodium sulfate drying, solvent is to the greatest extent steamed in decompression, gets solid product 3.24g (HPLC:99.3%), yield 89.4%.M.p.169.0-170.6 ℃, Rf=0.37 [single-point, developping agent: ETHYLE ACETATE: sherwood oil (60-90 ℃)=1: 1].
Embodiment 4:(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-THTP is [3,2-c] pyridine-5-yl also)]-N '-[(diethylammonium) methene base] acethydrazide
In the 250mL reaction flask that stirring, condensing surface, TM are housed, add 3.8g (0.01mol) intermediate III-2, add 15% hydrochloric acid soln 8mL (0.03mol), stir adding 0.5g (0.015mol) formaldehyde down.Be warming up to 70 ℃ and continue reaction 0.5h (the flaggy demonstration reacts completely).Stopped reaction, with 3 * 10mL dichloromethane extraction, anhydrous sodium sulfate drying, solvent is to the greatest extent steamed in decompression, gets solid product 3.38g (HPLC:99.0%), yield 86.6%.M.p.168.5-170.1 ℃, Rf=0.40 [single-point, developping agent: ETHYLE ACETATE: sherwood oil (60-90 ℃)=1: 1].
Claims (8)
1. preparation method suc as formula the I compound is characterized in that technical process and reaction conditions are undertaken by following mode:
Wherein R is methyl or ethyl
Intermediate II and Hydrazine Hydrate 80, acetone or propione reaction generate intermediate III, intermediate III and formaldehyde cyclization reaction production I compound.
2. the preparation method of a formula I compound as claimed in claim 1 is characterized in that:
(1) with the solution of intermediate II, be warming up to 50～60 ℃ of mixed solutions that add Hydrazine Hydrate 80 and acetone or propione, reaction makes intermediate III;
(2) intermediate III is dissolved in organic acid or mineral acid, with formaldehyde the Pictet-Spengler reaction takes place, and makes formula I compound.
3. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the solvent of said flow process (1) is that methylene dichloride, trichloromethane, toluene, dioxane are wherein a kind of.
4. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the concentration of the Hydrazine Hydrate 80 of said flow process (1) is 60-90%.
5. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: intermediate II, Hydrazine Hydrate 80 and the acetone of said flow process (1) or the mol ratio of propione are 1: (1-1.2): (1-1.2).
6. the preparation method of a formula I compound as claimed in claim 2 is characterized in that: the organic acid of said flow process (2) or mineral acid are wherein a kind of of formic acid, acetate, hydrochloric acid, sulfuric acid.
7. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the temperature of reaction of said flow process (2) is 30～100 ℃.
8. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the mol ratio of compound III, acid and the formaldehyde of said flow process (2) is 1: (1-4): (1-2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101823741A CN101812072B (en) | 2010-05-27 | 2010-05-27 | Method for preparing anti-platelet aggregation compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101823741A CN101812072B (en) | 2010-05-27 | 2010-05-27 | Method for preparing anti-platelet aggregation compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101812072A CN101812072A (en) | 2010-08-25 |
| CN101812072B true CN101812072B (en) | 2012-07-04 |
Family
ID=42619450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101823741A Active CN101812072B (en) | 2010-05-27 | 2010-05-27 | Method for preparing anti-platelet aggregation compounds |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101812072B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102796093B (en) * | 2012-08-23 | 2015-06-24 | 天津药物研究院 | Thiomorpholine-containing pyrrole derivatives and their preparation method and use |
| CN103665042B (en) * | 2012-09-21 | 2016-03-16 | 北京普禄德医药科技有限公司 | Optically active 2-hydroxy tetrahydro thienopyridine derivative and its production and use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1683373A (en) * | 2005-02-23 | 2005-10-19 | 天津药物研究院 | Thiophenopyridine substituted acetyl hyarazine derivative |
| CN101260112A (en) * | 2008-04-11 | 2008-09-10 | 天津药物研究院 | Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof |
-
2010
- 2010-05-27 CN CN2010101823741A patent/CN101812072B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1683373A (en) * | 2005-02-23 | 2005-10-19 | 天津药物研究院 | Thiophenopyridine substituted acetyl hyarazine derivative |
| CN101260112A (en) * | 2008-04-11 | 2008-09-10 | 天津药物研究院 | Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof |
Non-Patent Citations (2)
| Title |
|---|
| Die Cheng et al.Synthesis and activity evaluation of some novel derivatives of 4,5,6,7-tetrahydrothieno [3,2-c]-pyridine.《Chinese Chemical Letters》.2008,第19卷689-692. * |
| 成碟等.含有取代哌嗪及哌啶结构的噻吩并吡啶类化合物的合成及活性研究.《中国药学杂志》.2009,第44卷(第22期),1752-1754. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101812072A (en) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101967145B (en) | Method for preparing antithrombotic medicament apixaban | |
| CN107235959A (en) | A kind of novel method for synthesizing for preparing cancer therapy drug Niraparib | |
| CN101812072B (en) | Method for preparing anti-platelet aggregation compounds | |
| CN104529895B (en) | Synthetic method of replacing nitrogen-containing heterocyclic compound | |
| CN106928191B (en) | A kind of preparation process of Lansoprazole | |
| CN109575017A (en) | A kind of preparation method of Olprinone HCl compound | |
| CN104592144B (en) | New method for preparing oxazole derivative | |
| CN101973932B (en) | Preparation method of bisacodyl | |
| CN107118215B (en) | A kind of preparation method for treating breast cancer medicines Rui Boxini intermediate | |
| CN101781311B (en) | Novel preparation method of platelet aggregation inhibition compound | |
| CN106748721B (en) | A kind of preparation method of the chloro- 5- iodo-benzoic acid of 2- | |
| CN106554354B (en) | The preparation method of the intermediate of Li Gelieting or its analog and Li Gelieting or its analog | |
| CN106946880A (en) | A kind of method for preparing Rui Boxini intermediates | |
| CN113563319B (en) | Indazole heterocyclic compounds having phosphodiesterase 4B inhibitory activity | |
| CN103588758A (en) | Synthesis and preparation of nitroimidazole derivative containing 1,4-benzdioxan skeleton and application of nitroimidazole derivative in anticancer drugs | |
| CN106478515B (en) | A kind of preparation method of Azilsartan intermediate | |
| CN101704788B (en) | Improved preparation process of 2-Butyl-1,3-diazapira[4,4]nonane-1-en-4-one | |
| CN103724325B (en) | Prepare the method for sulfinyl-1-hydrogen-benzimidizole derivatives | |
| CN101812073B (en) | Method for preparing acethydrazide derivatives | |
| CN105732521A (en) | Preparation method of dihydrogen quinazolinone derivative | |
| CN102766163B (en) | Synthesis method of phosphate monoester of vitamin B1 | |
| CN106749220B (en) | 6 '-substituted benzimidazole -4- substituent methyl indole derivatives of one kind and its preparation and application | |
| CN103864786A (en) | Method for synthesizing 6-fluoroimidazo-[1,2-a]-pyridine-3-formic acid | |
| CN103435566A (en) | Synthesis technology for preparing oteracil potassium | |
| CN103288751B (en) | A kind of preparation method of high-purity nifekalant hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 300301 No. 306, Huiren Road, Binhai Science Park, Binhai high tech Zone, Binhai New Area, Tianjin Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220406 Address after: 300301 No. 29, Huixin Road, Binhai Science Park, Binhai high tech Zone, Tianjin Binhai New Area, Tianjin Patentee after: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH PHARMACEUTICAL RESPONSIBLE CO.,LTD. Address before: 300301 No. 306, Huiren Road, Binhai Science Park, Binhai high tech Zone, Binhai New Area, Tianjin Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. |